TY - JOUR
T1 - The significance of strong histone deacetylase 1 expression in the progression of prostate cancer
AU - Song, Yoohyun
AU - Shiota, Masaki
AU - Tamiya, Sadafumi
AU - Kuroiwa, Kentaro
AU - Naito, Seiji
AU - Tsuneyoshi, Masazumi
PY - 2011/4
Y1 - 2011/4
N2 - Aims: Histone deacetylases (HDACs) play important roles in many types of cancer. Recently, it has been reported that HDAC1 expression in prostate cancer is significantly higher than in benign prostate cell lines and tissues. The expression of HDAC1 in association with the clinicopathological data was investigated to define its functional and pathological roles in prostate cancer. Methods and results: HDAC1 expression was examined immunohistochemically in 148 patients with prostate cancer. Strong expression of HDAC1 in benign prostate glands, high-grade prostatic intraepithelial neoplasia (PIN) and prostate cancer was observed in 17/148 (11%), 19/71 (27%) and 69/148 (47%) patients. Strong HDAC1 expression was correlated with high Gleason score (P=0.025) and high pT stage (P=0.012). Patients with strong HDAC1 expression had higher biochemical recurrence rates (P=0.0010). Furthermore, strong HDAC1 expression had a significant impact on patient biochemical recurrence rates in multivariate analysis (P=0.004). Conclusions: These results indicate that overexpression of HDAC1 contributes to progression and poor prognosis in prostate cancer. The findings may play an important role in the emergence of effective new approaches for therapy and prognostic markers of prostate cancer.
AB - Aims: Histone deacetylases (HDACs) play important roles in many types of cancer. Recently, it has been reported that HDAC1 expression in prostate cancer is significantly higher than in benign prostate cell lines and tissues. The expression of HDAC1 in association with the clinicopathological data was investigated to define its functional and pathological roles in prostate cancer. Methods and results: HDAC1 expression was examined immunohistochemically in 148 patients with prostate cancer. Strong expression of HDAC1 in benign prostate glands, high-grade prostatic intraepithelial neoplasia (PIN) and prostate cancer was observed in 17/148 (11%), 19/71 (27%) and 69/148 (47%) patients. Strong HDAC1 expression was correlated with high Gleason score (P=0.025) and high pT stage (P=0.012). Patients with strong HDAC1 expression had higher biochemical recurrence rates (P=0.0010). Furthermore, strong HDAC1 expression had a significant impact on patient biochemical recurrence rates in multivariate analysis (P=0.004). Conclusions: These results indicate that overexpression of HDAC1 contributes to progression and poor prognosis in prostate cancer. The findings may play an important role in the emergence of effective new approaches for therapy and prognostic markers of prostate cancer.
UR - http://www.scopus.com/inward/record.url?scp=79954591057&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79954591057&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2559.2011.03797.x
DO - 10.1111/j.1365-2559.2011.03797.x
M3 - Article
C2 - 21438903
AN - SCOPUS:79954591057
SN - 0309-0167
VL - 58
SP - 773
EP - 780
JO - Histopathology
JF - Histopathology
IS - 5
ER -